By David Gillum, George Poste, Craig Woods, Rachel Levinson | Aug 31, 2023
Despite the dramatic pace of discoveries in the life sciences, the regulatory systems established for other dual-use risk domains, such as chemical and nuclear research, remain far more mature than those for oversight of the bioeconomy. Developing a well-balanced oversight system will not be easy. Nonetheless, the expanding gaps in national and international governance of dual-use biotechnology dictate that this subject be a core component of national security policies.